'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies

Annemans, L., Packard, C. J. , Briggs, A. and Ray, K. K. (2018) 'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. European Heart Journal, 39(27), pp. 2546-2550. (doi:10.1093/eurheartj/ehx710) (PMID:29236976) (PMCID:PMC6047410)

[img]
Preview
Text
154392.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.

293kB

Abstract

No abstract available.

Item Type:Articles
Additional Information:This work was supported by Regeneron Pharmaceuticals, Inc. and Sanofi.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Briggs, Professor Andrew and Packard, Professor Chris
Authors: Annemans, L., Packard, C. J., Briggs, A., and Ray, K. K.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Health Economics and Health Technology Assessment
Journal Name:European Heart Journal
Publisher:Oxford University Press
ISSN:0195-668X
ISSN (Online):1522-9645
Published Online:11 December 2017
Copyright Holders:Copyright © 2017 The Authors
First Published:First published in European Heart Journal 39(27): 2546-2550
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record